目的探讨贝那普利对慢性充血性心力衰竭患者左心室功能、血管内皮舒张功能的影响。方法 2010年12月至2011年12月期间,我院诊治的60例慢性充血性心力衰竭患者,随机将其分为对照组和观察组,分别给予常规治疗和常规治疗基础上家用贝那普利,治疗6个月后,对两组左心室功能、肱动脉内皮舒张功能,以及临床疗效,进行观察和比较。结果与治疗前相比,治疗后两组患者的心功能都有明显改善。与对照组相比,观察组患者的心功能有明显改善,t=2.32,P<0.05。与治疗前相比,治疗后两组患者的肱动脉血管内皮舒张功能都有改善。与对照组相比(7.46±4.38),观察组治疗后的肱动脉血管内皮舒张功能明显提高(22.35±18.77),t=2.12,P<0.05。30例对照组中,11例显效,12例有效,7例无效;30例观察组中,显效16例,有效13例,无效1例。与对照组相比(23/30,76.7%),观察组总有效率明显升高(29/30,96.7%),P<0.05。结论对于慢性充血性心力衰竭患者,常规抗心衰基础上,给予贝那普利能够显著提高临床疗效,值得临床推广。 Objective To investigate the effect of benazepril on left ventricular function and vascular endothelial relaxation in patients with chronic congestive heart failure. Methods From December 2010 to December 2011, 60 patients with chronic congestive heart failure treated in our hospital were randomly divided into control group and observation group, and were given routine and routine treatment based on benazepril After 6 months of treatment, the left ventricular function, the diastolic function of the brachial artery and the clinical curative effect were observed and compared. Results Compared with those before treatment, cardiac function in both groups improved significantly after treatment. Compared with the control group, patients in the observation group had significantly improved cardiac function, t = 2.32, P <0.05. Compared with before treatment, both groups of patients after treatment of brachial artery vascular endothelial function have improved. Compared with the control group (7.46 ± 4.38), the dilatation function of brachial artery in the observation group was significantly improved (22.35 ± 18.77), t = 2.12, P <0.05.Of the 30 cases of control group, 11 cases were markedly effective and 12 cases Effective, 7 cases were invalid; 30 cases of observation group, markedly effective in 16 cases, effective in 13 cases, 1 case of ineffective. Compared with the control group (23/30, 76.7%), the total effective rate in the observation group was significantly higher (29/30, 96.7%), P <0.05. Conclusions For patients with chronic congestive heart failure, the conventional anti-heart failure based on the administration of benazepril can significantly improve the clinical efficacy, worthy of clinical promotion.